Skip to content
Peptigraph home
Shop Peptides50% off*

Does retatrutide cause nausea?

Yes: in the phase 3 trial in type 2 diabetes, nausea occurred in 14%, 21% and 28% of participants across rising retatrutide dose groups against 8% on placebo.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Yes: in the phase 3 trial in type 2 diabetes, nausea occurred in 14%, 21% and 28% of participants across rising retatrutide dose groups against 8% on placebo.[1]

What the trials report

In the phase 2 diabetes trial, mild-to-moderate gastrointestinal events including nausea affected 35% of retatrutide participants against 13% on placebo, ranging from 13% to 50% by group.[2]

In the phase 2 obesity trial, gastrointestinal events were dose-related, mostly mild to moderate, and partly reduced when the starting dose was 2 mg rather than 4 mg.[3]

A review attributes the higher gastrointestinal event rates at top doses to rapid dose escalation and a higher starting dose.[4]

Across the phase 3 monotherapy trial, stopping treatment because of adverse events was 2-5% with retatrutide and 0% with placebo.[5]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  2. 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  3. 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  4. 4Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert review of clinical pharmacology · 2026PMID 41785010Accessed 2 Oct 2026
  5. 5Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026

Found an error? Report a correction.